MicroPort NeuroScientific Sets Up Strategy and Commercialization Committees, Adds Veteran Executive to Board

MicroPort NeuroTech Limited ( (HK:2172) ) has issued an update.

MicroPort NeuroScientific Corporation has created a new Strategic Committee and Commercialization Committee, effective 29 December 2025, to steer its medium- and long-term development and sharpen execution in bringing its neurotechnology products to market. The Strategic Committee will guide long-term strategic planning in stroke treatment and brain science, aligning with supportive policies and industry opportunities, while the Commercialization Committee will focus on optimizing commercialization systems and enhancing the competitive positioning of the company’s products. At the same time, the board has appointed veteran executive Thomas A. Liu as an independent non-executive director, adding extensive global experience in supply chain, manufacturing, industrial automation, capital deployment and M&A, a move that is expected to strengthen governance and support MicroPort NeuroScientific’s international expansion and operational upgrading.

The most recent analyst rating on (HK:2172) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on MicroPort NeuroTech Limited stock, see the HK:2172 Stock Forecast page.

More about MicroPort NeuroTech Limited

MicroPort NeuroScientific Corporation is a Cayman Islands-incorporated medical technology company focused on comprehensive stroke treatment solutions and brain science innovation. The group is expanding its capabilities in areas such as brain-computer interfaces, evidenced by the establishment of its Chaos Brain-Computer Research Institute, and is actively promoting a global business layout to strengthen its international brand presence in neurotechnology and related medical devices.

Average Trading Volume: 2,442,878

Technical Sentiment Signal: Sell

Current Market Cap: HK$6.23B

For a thorough assessment of 2172 stock, go to TipRanks’ Stock Analysis page.